Free Trial

Titan Pharmaceuticals (TTNP) Competitors

Titan Pharmaceuticals logo
$5.92 +1.14 (+23.70%)
Closing price 10/1/2025
Extended Trading
$5.92 0.00 (0.00%)
As of 10/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TTNP vs. PMN, DARE, RNTX, CVKD, QTTB, ENLV, KZR, LPTX, XCUR, and GLTO

Should you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Promis Neurosciences (PMN), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Cadrenal Therapeutics (CVKD), Q32 Bio (QTTB), Enlivex Therapeutics (ENLV), Kezar Life Sciences (KZR), Leap Therapeutics (LPTX), Exicure (XCUR), and Galecto (GLTO). These companies are all part of the "pharmaceutical products" industry.

Titan Pharmaceuticals vs. Its Competitors

Titan Pharmaceuticals (NASDAQ:TTNP) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

In the previous week, Promis Neurosciences had 3 more articles in the media than Titan Pharmaceuticals. MarketBeat recorded 4 mentions for Promis Neurosciences and 1 mentions for Titan Pharmaceuticals. Promis Neurosciences' average media sentiment score of 0.97 beat Titan Pharmaceuticals' score of 0.82 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Titan Pharmaceuticals Positive
Promis Neurosciences Positive

Promis Neurosciences has a consensus price target of $4.33, suggesting a potential upside of 844.08%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Titan Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Titan Pharmaceuticals' return on equity of -108.60% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Titan PharmaceuticalsN/A -108.60% -95.64%
Promis Neurosciences N/A -266.69%-131.59%

Titan Pharmaceuticals has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.

31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan PharmaceuticalsN/AN/A-$4.71M-$2.95-2.01
Promis NeurosciencesN/AN/A$2.78M-$0.21-2.19

Summary

Promis Neurosciences beats Titan Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Titan Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTNP vs. The Competition

MetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.88M$3.35B$6.04B$10.50B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-2.0121.9084.3627.24
Price / SalesN/A263.75502.46196.48
Price / CashN/A46.9537.5761.53
Price / Book2.2210.4312.356.74
Net Income-$4.71M-$52.58M$3.32B$276.59M
7 Day PerformanceN/A-1.55%-1.35%-0.47%
1 Month Performance33.45%12.96%8.12%7.47%
1 Year Performance25.80%15.43%73.78%34.58%

Titan Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTNP
Titan Pharmaceuticals
0.79 of 5 stars
$5.93
+23.7%
N/A+21.5%$7.88MN/A-2.0110High Trading Volume
PMN
Promis Neurosciences
3.4794 of 5 stars
$0.56
+2.8%
$4.33
+668.3%
-54.1%$30.73MN/A-2.725
DARE
Dare Bioscience
1.8443 of 5 stars
$2.25
-0.2%
$10.00
+345.4%
-41.6%$30.26M$10K-1.0530Positive News
Gap Down
RNTX
Rein Therapeutics
3.1353 of 5 stars
$1.29
+8.4%
$10.00
+675.2%
N/A$30.07MN/A-0.489
CVKD
Cadrenal Therapeutics
2.2958 of 5 stars
$13.71
+1.3%
$32.00
+133.5%
-2.8%$28.10MN/A-1.544
QTTB
Q32 Bio
2.9624 of 5 stars
$2.27
+4.4%
$12.17
+437.2%
-91.6%$27.63M$1.16M-0.5339Analyst Forecast
ENLV
Enlivex Therapeutics
2.8563 of 5 stars
$1.13
-1.2%
$10.00
+784.2%
-23.4%$27.57MN/A-1.9670
KZR
Kezar Life Sciences
3.6953 of 5 stars
$3.75
-4.6%
$9.00
+140.0%
-50.2%$27.47MN/A-0.3960Gap Down
LPTX
Leap Therapeutics
2.6021 of 5 stars
$0.66
-13.4%
$3.38
+410.6%
-73.5%$27.39MN/A-0.4240High Trading Volume
XCUR
Exicure
1.9125 of 5 stars
$4.21
-1.5%
N/A+97.7%$27.18M$500K-1.1150
GLTO
Galecto
0.5705 of 5 stars
$21.06
+467.5%
$10.00
-52.5%
+61.0%$27.10MN/A-1.5640Analyst Forecast
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:TTNP) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners